Coughlin Stoia Geller Rudman & Robbins LLP
Files Class Action Suit Against Cell Therapeutics,
Inc.
March 12, 2010 06:14 PM Eastern Time
NEW YORK--(EON: Enhanced Online News)--Coughlin Stoia Geller Rudman & Robbins LLP (“Coughlin Stoia”)
(http://www.csgrr.com/cases/cellthera/) today announced that a class action has been commenced in the United
States District Court for the Western District of Washington on behalf of purchasers of the common stock of Cell
Therapeutics, Inc. (“Cell Therapeutics ” or the “Company”) (NASDAQ: CTIC) between May 5, 2009 and
February 8, 2010, inclusive (the “Class Period”), seeking to pursue remedies under the Securities Exchange Act of
1934 (the “Exchange Act”).
If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from today. If you wish to
discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s
counsel, Samuel H. Rudman or David A. Rosenfeld of Coughlin Stoia at 800/449-4900 or 619/231-1058, or via e-
mail at djr@csgrr.com. If you are a member of this Class, you can view a copy of the complaint as filed or join this
class action online at http://www.csgrr.com/cases/cellthera/. Any member of the putative class may move the Court
to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class
member.
The complaint charges Cell Therapeutics and certain of its officers and executives with violations of the Exchange
Act. Cell Therapeutics develops, acquires, and commercializes oncology products for cancer treatment.
One of the products that the Company developed is pixantrone, a phase III trial product for non-Hodgkin’s
lymphoma. The Company describes pixantrone as a “novel topoisomerase II inhibitor with an aza-anthracenedione
molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents.” The
Company represents that pixantrone, unlike other anthracyclines, is not “car